Novateor Research Laboratories Ltd H1 FY26 – ₹2.47 Cr Revenue, -₹0.03 EPS, 484x P/E & A Balance Sheet That’s Trying Really Hard
1. At a Glance
Novateor Research Laboratories Ltd is that classic SME stock which looks like it woke up one fine morning, saw FMCG valuations on TV, and said, “Why not me?” Market cap of roughly ₹14.5 Cr, current price hovering around ₹24, and a P/E ratio so high (around 484) that even large-cap FMCG giants are squinting at it with disbelief. The last six months have not been kind to the stock price, with returns looking like a dentist bill after insurance rejection. Yet, operationally, the company suddenly decided to show some life: quarterly sales shot up 213% year-on-year, landing at ₹2.47 Cr. Profits? Well… still missing in action, with a quarterly loss of about ₹0.02 Cr. ROCE and ROE are both stuck below 2%, which means capital is technically working, but only at the speed of a government website at 3 a.m.
This is a company that sells teeth-whitening dreams but still hasn’t figured out how to whiten its own profit statement consistently. Intrigued already? Good. Because this story has promoters, preferential allotments, auditor drama, and a balance sheet that reads like a slow-burn thriller.
2. Introduction
Novateor Research Laboratories Ltd was incorporated in 2011, and if corporate lives were Bollywood movies, this one would fall into the “slow first half, interval confusion, second half twist” category. The company operates in oral care and personal care products, a segment where branding, distribution, and trust matter more than almost anything else.
On paper, it sounds glamorous: FDA-approved products, teeth whitening strips, gels, kids toothpaste, power brushes, and a brand name called Smile Shine. In reality, the company has spent many years experimenting with business models, reporting losses, and surviving largely on other income and capital infusions.
FY25 and H1 FY26 show a company attempting a comeback arc. Revenues are finally visible, sales growth numbers look explosive, and management has expanded the objects of the company to include dental equipment trading and even chemicals and coatings. That’s not diversification—that’s a buffet.
But here’s the question every sane investor asks: is this a focused growth story, or is it a survival strategy disguised as ambition? Keep reading.
3. Business Model – WTF Do They Even Do?
At its core, Novateor develops and sells oral care and personal care products. The hero category is teeth whitening. Whitening strips, gels, toothpaste, brushes—the full Instagram smile starter pack. These products are sold under the brand Smile Shine and are targeted primarily at dentists and cosmetic parlours rather than mass retail.
This B2B-ish model means volumes are limited, but margins should theoretically be better. However, theory and Novateor’s P&L have not been close friends historically.
The company manufactures multiple SKUs but does not yet enjoy scale. Manufacturing is planned to be shifted to a new facility at GIDC Sanand, Ahmedabad district, which suggests management is at least thinking about operational consolidation.
Then comes the plot twist. In FY25, Novateor amended its Memorandum of Association to add two completely new business segments:
Dental and healthcare products trading (equipment, instruments, consumables, diagnostics).
Chemicals and coatings, including paints, adhesives, waterproofing, and application services.
This is where the lazy investor scratches their head. Oral care to industrial coatings is not adjacency; it’s a long jump with no warm-up. Is management opportunistic, or just trying to keep revenue flowing from wherever possible? What do you think?
4. Financials Overview
Result Type Lock
The latest official result announcement clearly states Half Yearly Results for the period ended September 30, 2025. This is treated as HALF-YEARLY RESULTS and locked here. EPS annualisation, where discussed, uses latest EPS × 2.
H1 FY26 Performance Comparison Table (₹ in Crores)
Source table
Metric
Latest H1 FY26
H1 FY25
Previous H2 FY25
YoY %
QoQ %
Revenue
2.47
0.79
1.98
212.7%
24.7%
EBITDA
-0.12
-0.11
-0.02
NA
NA
PAT
-0.02
0.03
0.05
-166.7%
-140%
EPS (₹)
-0.03
0.06
0.10
NA
NA
Yes, revenue growth looks spectacular. But EBITDA and PAT are still negative. This is like opening a new restaurant, filling all tables on day one, and still losing money because you forgot to price the menu properly.
Commentary: Sales growth without operating leverage is just cardio for the income statement—lots of movement, no muscle.
5. Valuation Discussion – Fair Value Range Only
Let’s talk valuation, because the current market is definitely talking… loudly.
Method 1: P/E
Latest EPS (TTM): ₹0.07 Annualised EPS (H1 basis ×2): roughly similar zone
At ₹24 CMP, the stock trades at ~484x earnings. Even premium FMCG giants don’t get this kind of love. Assigning any “fair” P/E here becomes philosophical rather than analytical.
Method 2: EV/EBITDA
Enterprise Value: ~₹14.9 Cr EBITDA: Negative
When EBITDA is negative, EV/EBITDA becomes more of a warning sign than a valuation tool.
Method 3: DCF
Given inconsistent cash flows, negative operating cash
